From Biology to Breakthroughs
Advancing biomarkers from discovery to clinical application requires technologies that deliver clarity and context across biological systems.
At Quanterix, we unify Simoa ultrasensitive immunoassays and spatial proteomics to support the full biomarker journey from liquid-based detection to tissue-level insight.
Multimodal Biomarkers for Translational Success
Simoa quantifies low-abundance proteins at femtogram levels across plasma, CSF, saliva, and other fluids enabling:
- Early disease detection
- Longitudinal monitoring
- Treatment response evaluation
- Companion diagnostic development
Our spatial biology platforms deliver high-plex, single-cell protein analysis in tissue, mapping biomarkers to specific:
- Cell types
- Structures
- Immune microenvironments
Together, these platforms create a precision biomarker ecosystem that bridges systemic signals and local tissue biology; empowering translational teams to move faster and smarter.
Clinical Relevance Built In
With Simoa and spatial technologies, you can:
- Detect biomarkers in plasma and validate pathology in brain tissue
- Monitor cytokines in blood while visualizing immune infiltration in tumors
- Use a single sample to inform both systemic progression and cellular context
This dual approach strengthens:
- Patient stratification
- PK/PD and target engagement
- Trial design and endpoint selection
And with CLIA-validated workflows, custom assay development, and automation-ready platforms, our tools are built to scale from research to regulated use without switching platforms.
Powerful Alone and Transformative Together
Quanterix delivers unmatched resolution in both liquid and tissue – turning molecular signals into predictive, interpretable, and clinically relevant biomarkers.
